VCNX (Vaccinex) Short-Term Debt : $0.04 Mil (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Vaccinex Short-Term Debt?

Vaccinex's Short-Term Debt for the quarter that ended in Sep. 2024 was $0.04 Mil.

Vaccinex's quarterly Short-Term Debt declined from Mar. 2024 ($0.08 Mil) to Jun. 2024 ($0.06 Mil) and declined from Jun. 2024 ($0.06 Mil) to Sep. 2024 ($0.04 Mil).

Vaccinex's annual Short-Term Debt stayed the same from Dec. 2021 ($0.07 Mil) to Dec. 2022 ($0.07 Mil) but then increased from Dec. 2022 ($0.07 Mil) to Dec. 2023 ($0.08 Mil).

Vaccinex Short-Term Debt Historical Data

The historical data trend for Vaccinex's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaccinex Short-Term Debt Chart

Vaccinex Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

8.07

0.07

0.08

Vaccinex Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Short-Term Debt	Get a 7-Day Free Trial															0.08	0.08	0.08	0.06	0.04

Vaccinex Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Vaccinex Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Vaccinex's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Vaccinex Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaccinex Inc (NAS:VCNX) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

1895 Mount Hope Avenue, Rochester, NY, USA, 14620

Website

https://www.vaccinex.com

Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.

Executives

Albert Friedberg	director, 10 percent owner
Van Strydonck, Gerald E.	director	1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Maurice Zauderer	director, 10 percent owner, officer: President and CEO	1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Jacob B. Frieberg	director	1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Elizabeth E. Evans	officer: Chief Operating Officer	C/O VACCINEX, INC., 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Robert Scala	officer: Chief Commercial Officer	1895 MT HOPE AVENUE, ROCHESTER NY 14620
Chrystyna Bedrij Stecyk	director	1895 MT. HOPE AVENUE, ROCHESTER NY 14620
Vaccinex, Inc.	director	1895 MOUNT HOPE AVE, ROCHESTER NY 14620
Jeff Goater	director	C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Bala S Manian	director	1025 TERRA BELLA AVE, MOUNTAIN VIEW CA 94043
Barbara Yanni	director	1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Alejandro M. Berlin	director	1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
John E. Leonard	officer: SVP, Development	1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Ernest S. Smith	officer: SVP, Research & CSO	1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Raymond E. Watkins	officer: SVP & Chief Operating Officer	1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620